Anixa Biosciences Secures Canadian Patent for Ovarian Cancer Vaccine Technology
Summary
Anixa Biosciences received a Canadian Notice of Allowance for a patent covering its ovarian cancer vaccine technology. This expands the company's international intellectual property portfolio, complementing existing U.S. patent protection for this key pipeline asset. The allowance strengthens the commercial potential and de-risks the ovarian cancer vaccine, which is being developed in collaboration with Cleveland Clinic and the NCI. This positive development follows recent favorable clinical updates for Anixa's breast cancer vaccine and CAR-T therapy.
At the time of this announcement, ANIX was trading at $2.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.5M. The 52-week trading range was $2.44 to $5.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.